TEMPUS AI, INC. CLASS A COMMON STOCK

NASDAQ: TEM (Tempus AI, Inc.)

Kemas kini terakhir: 7 jam lalu

60.98

0.33 (0.54%)

Penutupan Terdahulu 60.65
Buka 61.70
Jumlah Dagangan 8,226,730
Purata Dagangan (3B) 12,938,838
Modal Pasaran 10,556,613,632
Harga / Jualan (P/S) 11.13
Harga / Buku (P/B) 32.35
Julat 52 Minggu
31.36 (-48%) — 91.45 (49%)
Tarikh Pendapatan 4 Aug 2025 - 19 Aug 2025
Margin Keuntungan -88.27%
Margin Operasi (TTM) -26.93%
EPS Cair (TTM) -5.16
Pertumbuhan Hasil Suku Tahunan (YOY) 75.40%
Jumlah Hutang/Ekuiti (D/E MRQ) 262.96%
Nisbah Semasa (MRQ) 1.71
Aliran Tunai Operasi (OCF TTM) -193.29 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 54.30 M
Pulangan Atas Aset (ROA TTM) -43.89%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Health Information Services (US) Menaik Bercampur
Health Information Services (Global) Menaik Bercampur
Stok Tempus AI, Inc. Menaik -

AISkor Stockmoo

-0.2
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -3.0
Volatiliti Harga 2.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal -0.5
Purata -0.20

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TEM 11 B - - 32.35
HQY 9 B - 74.57 3.96
WAY 6 B - 282.31 2.08
RCM 6 B - - 2.14
PRVA 3 B - 191.25 3.98
WGS 3 B - - 9.06

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Sektor Healthcare
Industri Health Information Services
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 43.27%
% Dimiliki oleh Institusi 38.02%

Pemilikan

Nama Tarikh Syer Dipegang
Revolution Growth Management Company, Inc. 31 Mar 2025 1,467,565
72.5572.5564.9064.9057.2557.2549.6049.6041.9541.95Harga Sasaran MedianQ3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
31.36 (-48%) — 91.45 (49%)
Julat Harga Sasaran
60.00 (-1%) — 75.00 (22%)
Tinggi 75.00 (Guggenheim, 22.99%) Beli
Median 70.00 (14.79%)
Rendah 60.00 (BTIG, -1.61%) Beli
Purata 68.33 (12.05%)
Jumlah 4 Beli, 2 Pegang
Harga Purata @ Panggilan 58.79
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Guggenheim 30 Jun 2025 75.00 (22.99%) Beli 63.54
B of A Securities 25 Jun 2025 70.00 (14.79%) Pegang 65.47
20 May 2025 68.00 (11.51%) Pegang 62.43
Piper Sandler 15 May 2025 70.00 (14.79%) Pegang 62.60
Morgan Stanley 09 May 2025 65.00 (6.59%) Beli 61.37
Needham 07 May 2025 70.00 (14.79%) Beli 58.76
24 Apr 2025 70.00 (14.79%) Beli 53.50
BTIG 21 Apr 2025 60.00 (-1.61%) Beli 40.98
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
FUKUSHIMA RYAN - 58.01 -5,000 -290,050
Jumlah Keseluruhan Kuantiti Bersih -5,000
Jumlah Keseluruhan Nilai Bersih ($) -290,050
Purata Pembelian Keseluruhan ($) -
Purata Jualan Keseluruhan ($) 58.01
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
FUKUSHIMA RYAN Pegawai 07 Jul 2025 Jual automatik (-) 5,000 58.01 290,050
Tarikh Jenis Butiran
16 Jul 2025 Pengumuman Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
16 Jul 2025 Pengumuman From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine
09 Jul 2025 Pengumuman Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
08 Jul 2025 Pengumuman Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
30 Jun 2025 Pengumuman Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
30 Jun 2025 Pengumuman Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
25 Jun 2025 Pengumuman Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
17 Jun 2025 Pengumuman Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
13 Jun 2025 Pengumuman Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
12 Jun 2025 Pengumuman Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
02 Jun 2025 Pengumuman Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
01 Jun 2025 Pengumuman Introducing Tempus One in the EHR with Integrated Guidelines
31 May 2025 Pengumuman Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
30 May 2025 Pengumuman Real-World Deployments Signal AI Healthcare Is Ready for Scale
30 May 2025 Pengumuman Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
28 May 2025 Pengumuman A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
28 May 2025 Pengumuman Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Tempus AI, Inc. (Nasdaq: TEM)
21 May 2025 Pengumuman Tempus to Present at the William Blair 45th Annual Growth Stock Conference
21 May 2025 Pengumuman Options Trading Now Available on Three Tradr ETFs: QBTX, TEMT and APPX
20 May 2025 Pengumuman Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
20 May 2025 Pengumuman From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
14 May 2025 Pengumuman Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
13 May 2025 Pengumuman Tradr Launches First Leveraged ETF on Tempus AI
13 May 2025 Pengumuman Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
12 May 2025 Pengumuman Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
06 May 2025 Pengumuman Tempus Reports First Quarter 2025 Results
05 May 2025 Pengumuman Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
05 May 2025 Pengumuman AI Healthcare Boom Gains Speed as Regulators and Innovators Align
01 May 2025 Pengumuman Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
29 Apr 2025 Pengumuman Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
28 Apr 2025 Pengumuman Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
25 Apr 2025 Pengumuman Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
24 Apr 2025 Pengumuman Tempus to Report First Quarter 2025 Financial Results on May 6
23 Apr 2025 Pengumuman Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
Papar semua
65.2065.2061.7761.7758.3458.3454.9154.9151.4851.48Jul 9Jul 9Jul 10Jul 10Jul 11Jul 11Jul 14Jul 14Jul 15Jul 15Jul 16Jul 16Jul 17Jul 17Jul 18Jul 18

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
2.0002.0001.0001.0000.0000.000-1.000-1.000-2.000-2.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda